Exploring the immune landscape and drug prediction of an M2 tumor‐associated macrophage‐related gene signature in EGFR ‐negative lung adenocarcinoma
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15375 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Yajie Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Tumor-Associated Macrophages, ErbB Receptors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Commission Medical Science Research Project of Hebei Province.
Abstract (Originalsprache)
Background
Improving immunotherapy efficacy for EGFR‐negative lung adenocarcinoma (LUAD) patients remains a critical challenge, and the therapeutic effect of immunotherapy is largely determined by the tumor microenvironment (TME). Tumor‐associated macrophages (TAMs) are the top‐ranked immune infiltrating cells in the TME, and M2‐TAMs exert potent roles in tumor promotion and chemotherapy resistance. An M2‐TAM‐based prognostic signature was constructed by integrative analysis of single‐cell RNA‐seq (scRNA‐seq) and bulk RNA‐seq data to reveal the immune landscape and select drugs in EGFR‐negative LUAD.
Methods
M2‐TAM‐based biomarkers were obtained from the intersection of bulk RNA‐seq data and scRNA‐seq data. After consensus clustering of EGFR‐negative LUAD into different clusters based on M2‐TAM‐based genes, we compared the prognosis, clinical features, estimate scores, immune infiltration, and checkpoint genes among the clusters. Next, we combined univariate Cox and LASSO regression analyses to establish an M2‐TAM‐based prognostic signature.
Results
CCL20, HLA‐DMA, HLA‐DRB5, KLF4, and TMSB4X were verified as prognostic M2‐like TAM‐related genes by univariate Cox and LASSO regression analyses. IPS and TMB analyses revealed that the high‐risk group responded better to common immunotherapy.
Conclusion
The study shows the potential of the M2‐like TAM‐related gene signature in EGFR‐negative LUAD, explores the immune landscape based on M2‐like TAM‐related genes, and predict immunotherapy response of patients with EGFR‐negative LUAD, providing a new insight for individualized treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Infectious Diseases, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Endoscopy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
ORCID-Profile: Yajie Huang
Förderung
- Health Commission Medical Science Research Project of Hebei Province
Zitieren
APA
Huang, Y., Zhang, Y., Duan, X., Hou, R., Wang, Q., & Shi, J. (2024). Exploring the immune landscape and drug prediction of an M2 tumor‐associated macrophage‐related gene signature in EGFR ‐negative lung adenocarcinoma. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15375
Vancouver
Huang Y, Zhang Y, Duan X, Hou R, Wang Q, Shi J. Exploring the immune landscape and drug prediction of an M2 tumor‐associated macrophage‐related gene signature in EGFR ‐negative lung adenocarcinoma. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15375
BibTeX
@article{Huang2024,
author = {Huang, Yajie and Zhang, Yaozhong and Duan, Xiaoyang and Hou, Ran and Wang, Qi and Shi, Jian},
title = {Exploring the immune landscape and drug prediction of an M2 tumor‐associated macrophage‐related gene signature in EGFR ‐negative lung adenocarcinoma},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15375}
}
EUVIMED